Kalman syndrome is genetically heterogeneous, with a clear genetic diagnosis available for about 1/3 to 1/2 of patients, and some patients have double or multiple mutations. In practical practice, it is very difficult to evaluate the weight of each genetic mutation in the development of the disease, so it is very difficult to assess the risk of disease in the next generation in patients with successful fertility treatment; of course, for patients with a clear diagnosis of the causative gene monogenic Patients with a clear diagnosis of the causative gene can be considered for third generation IVF technology – preimplantation embryo genetic testing to screen healthy embryos for transfer to avoid inheritance of the defective gene, whereas for patients with an unclear diagnosis of the causative gene or multiple causative genes, effective screening cannot be made.